adamantane has been researched along with Heart Diseases in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arya, DS; Bhargava, P; Bhatia, J; Kumar, R; Suchal, K | 1 |
| Hardy, G | 1 |
| Smahelová, A; Spinar, J | 1 |
| Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H | 1 |
| Chiamvimonvat, N; Cummings, BP; Despa, F; Despa, S; Dong, H; Dutrow, G; Evans, JE; Graham, J; Guglielmino, K; Hammock, BD; Harris, TR; Havel, PJ; Jackson, K; Vu, V | 1 |
1 trial(s) available for adamantane and Heart Diseases
| Article | Year |
|---|---|
[SAVOR TIMI 53 - Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus].
Topics: Adamantane; Aged; Cross-Sectional Studies; Czech Republic; Diabetes Mellitus, Type 2; Dipeptides; Female; Heart Diseases; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Survival Analysis | 2013 |
4 other study(ies) available for adamantane and Heart Diseases
| Article | Year |
|---|---|
Targeting AGE-RAGE signaling pathway by Saxagliptin prevents myocardial injury in isoproterenol challenged diabetic rats.
Topics: Adamantane; Animals; Apoptosis; Diabetes Complications; Diabetes Mellitus, Experimental; Dipeptides; Heart Diseases; Isoproterenol; Male; NF-kappa B; Oxidative Stress; Rats; Rats, Wistar; Receptor for Advanced Glycation End Products; Signal Transduction | 2021 |
Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Diseases; Humans; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome | 2013 |
Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet.
Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Heart Diseases; Heart Rate; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Vildagliptin | 2012 |
Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats.
Topics: Adamantane; Animals; Blood Glucose; Blotting, Western; Calcium Signaling; Crosses, Genetic; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Eicosanoids; Enzyme Inhibitors; Epoxide Hydrolases; Heart Diseases; Hypoglycemic Agents; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Mitochondria, Heart; Myocytes, Cardiac; Myofibrils; Rats; Rats, Sprague-Dawley; Rats, Zucker; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Time Factors; Urea | 2012 |